Among the metal-based anticancer compounds explored in the last 40 years, ruthenium complexes emerged as one of the most promising classes . Trithiolato-bridged dinuclear ruthenium(II)-arene complexes (e.g., compounds M-O in Figure ) present a structure based on two half-sandwich ruthenium(II)-arene units bridged by three thiols, the Ru2S3 unit forming a trigonal-bipyramidal framework. Two types of complexes can be distinguished, namely 'symmetric' in which the three thiols are identical (M, N in Figure ), and 'mixed' bearing at least one different thiol (O, Figure ). This type of compounds are highly active against cancer cells but show limited selectivity . Recent studies revealed that they also exhibit remarkable antiparasitic properties against Toxoplasma gondii, Neospora caninum and Trypanosoma brucei . For example, on T. gondii and N. caninum complexes M, N and O (Figure ) exerted not only high antiparasitic activity but also interesting selectivity profiles. For instance, complex O had very low IC50 values of 1.2 nM for T. gondii and 1 nM for N. caninum .